Skip to main content
SpringerLink
Log in

Gastric Cancer

  • Chapter
  • First Online:
60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center

  • 1185 Accesses

Abstract

Gastric (stomach) cancer, the most frequently occurring cancer and second-leading cause of cancer-related deaths, accounts for 24.2 % of cancer deaths worldwide [1–3]. Adenocarcinoma accounts for the vast majority of gastric cancer cases, with the remaining minority consisting of lymphoma, sarcoma, carcinoid tumor, and squamous cell carcinoma; the treatment information in this chapter focuses only on adenocarcinoma, whereas the survival curves include patients with all histologies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Agency for Research on Cancer (IARC). http://www.iarc.fr/. Accessed 23 May 2012.

  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  3. Shibata A, Parsonnet J. Stomach cancer. 3rd ed. New York: Oxford University Press; 2006.

    Google Scholar 

  4. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C. Trends in cancer mortality in the Americas, 1970–2000. Ann Oncol. 2005;16(3):489–511.

    Article  PubMed  CAS  Google Scholar 

  5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  6. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1–27.

    PubMed  CAS  Google Scholar 

  7. Coggon D, Barker DJ, Cole RB, Nelson M. Stomach cancer and food storage. J Natl Cancer Inst. 1989;81(15):1178–82.

    Article  PubMed  CAS  Google Scholar 

  8. Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991;83(23):1734–9.

    Article  PubMed  CAS  Google Scholar 

  9. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.

    Article  PubMed  CAS  Google Scholar 

  10. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41.

    Article  PubMed  CAS  Google Scholar 

  11. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130(4):612–7 [discussion 7–9].

    Article  PubMed  CAS  Google Scholar 

  12. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904–9.

    Article  PubMed  CAS  Google Scholar 

  13. Chun YS, Lindor NM, Smyrk TC, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer. 2001;92(1):181–7.

    Article  PubMed  CAS  Google Scholar 

  14. Edge SB, Byrd DR, Compton C, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  15. SEER. SEER statistics facts sheet. http://www.seer.cancer.gov/statfacts/html/stomach.html. Accessed 27 Dec 2009.

  16. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230(2):170–8.

    Article  PubMed  CAS  Google Scholar 

  17. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg. 1989;209(2):162–6.

    Article  PubMed  CAS  Google Scholar 

  18. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol. 1996;23(3):360–8.

    PubMed  CAS  Google Scholar 

  19. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.

    Article  PubMed  CAS  Google Scholar 

  20. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.

    Article  PubMed  CAS  Google Scholar 

  21. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  PubMed  CAS  Google Scholar 

  22. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  PubMed  CAS  Google Scholar 

  23. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.

    Article  PubMed  CAS  Google Scholar 

  24. Ajani JA. Recent developments in cytotoxic therapy for advanced gastric or gastroesophageal carcinoma: the phase III trials. Gastrointest Cancer Res. 2007;1(Suppl):S16–21.

    PubMed  Google Scholar 

  25. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    Article  PubMed  CAS  Google Scholar 

  26. Moertel CG, Lavin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group. Cancer Treat Rep. 1979;63(11–12):1863–9.

    PubMed  CAS  Google Scholar 

  27. Schnitzler G, Queisser W, Heim ME, et al. Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep. 1986;70(4):477–9.

    PubMed  CAS  Google Scholar 

  28. Klein HO, Wils J, Bleiberg H, Buyse M, Duez N. An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer. Med Oncol Tumor Pharmacother. 1989;6(2):171–4.

    PubMed  CAS  Google Scholar 

  29. Barone C, Cassano A, Astone A, et al. Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology. 1991;48(5):353–5.

    Article  PubMed  CAS  Google Scholar 

  30. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71(12):3813–8.

    Article  PubMed  CAS  Google Scholar 

  31. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol. 2000;11(3):301–6.

    Article  PubMed  CAS  Google Scholar 

  32. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.

    Article  PubMed  Google Scholar 

  33. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25(22):3217–23.

    Article  PubMed  CAS  Google Scholar 

  34. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.

    Article  PubMed  CAS  Google Scholar 

  35. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.

    Article  PubMed  CAS  Google Scholar 

  36. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450–7.

    Article  PubMed  CAS  Google Scholar 

  37. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

    Article  PubMed  CAS  Google Scholar 

  38. van Cutsem E, Kang YK, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol. 2009;27(18s):LBA4509.

    Google Scholar 

  39. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18(14):2648–57.

    PubMed  CAS  Google Scholar 

  40. Smith JK, McPhee JT, Hill JS, et al. National outcomes after gastric resection for neoplasm. Arch Surg. 2007;142(4):387–93.

    Article  PubMed  Google Scholar 

  41. Brennan MF, Radzyner M, Rubin DM. Outcome—more than just operative mortality. J Surg Oncol. 2009;99(8):470–7.

    Article  PubMed  Google Scholar 

  42. Bare M, Cabrol J, Real J, et al. In-hospital mortality after stomach cancer surgery in Spain and relationship with hospital volume of interventions. BMC Public Health. 2009;9:312.

    Article  PubMed  Google Scholar 

  43. Verhoef C, van de Weyer R, Schaapveld M, Bastiaannet E, Plukker JT. Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. Ann Surg Oncol. 2007;14(5):1678–87.

    Article  PubMed  Google Scholar 

  44. Smith DL, Elting LS, Learn PA, Raut CP, Mansfield PF. Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol. 2007;14(6):1846–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Mailstop 426, Houston, TX, 77030, USA

    Alexandria T. Phan

  2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Paul F. Mansfield

Authors
  1. Alexandria T. Phan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul F. Mansfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandria T. Phan .

Editor information

Editors and Affiliations

  1. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    M. Alma Rodriguez

  2. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Ronald S. Walters

  3. Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Thomas W. Burke

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Phan, A.T., Mansfield, P.F. (2013). Gastric Cancer. In: Rodriguez, M., Walters, R., Burke, T. (eds) 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5197-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5197-6_18

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5196-9

  • Online ISBN: 978-1-4614-5197-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation